The primary objective of this study was to determine the optimal dose of the carcinoembryonic antigen (CEA) peptide (CAP1-6D)/Montanide/GM-CSF-vaccine amongst the three doses administered to induce a maximal CTL response in patients with pancreatic cancer. The gene discussed is CAP1; the disease is pancreatic neoplasm.